Axiom Biosciences拟2027年来港IPO
2026-07-21 13:55:28
据明报报道，总部位于圣地亚哥的美国生物科技公司Axiom Biosciences罕有考虑在香港进行IPO，目的是接触中国大陆快速发展的临床研发能力。Axiom计划于2027年来港上市，募集资金拟用于其核心药物的临床试验，该药物是一种用于神经疾病的干细胞疗法。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
预测市场：LoL小组赛四杀“是”选项升至90%Next article：
AI趋势 | Hugging Face披露AI Agent安全事件
